To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
11 Current news of Pall
rss
Pall Opens New Centre of Excellence in India to Serve Fast-Growing Life Sciences Market
21-05-2007
As part of its global initiative to align with customers worldwide, Pall Corporation inaugurated its newest Life Sciences Centre of Excellence in Bangalore, India. The Centre shall drive process optimization innovations for the global life sciences market to meet the evolving opportunities ...
Pall Files Patent Infringement Suit Against BioQuate
20-03-2007
Pall Corporation filed a patent infringement action in the United States District Court for the Eastern District of Pennsylvania against BioQuate, Inc., based in Clearwater, Florida. The suit alleges that BioQuate is manufacturing and selling disposable aseptic connector devices that infringe ...
First FDA Clearance of Sterile Field Cord Blood Collection Bag
ViaCell and Pall Announce Collaborative Agreement
27-04-2006
ViaCell, Inc. and Pall Corporation announced the first U.S. Food and Drug Administration clearance of a cord blood collection bag suitable for use in a sterile field. Pall and ViaCell collaborated on the development and design of the new collection bag. ViaCell has exclusive rights to the new ...
Pall Systems Play Key Role in Landmark NIH Study on Cord Blood
19-08-2005
As cord blood increasingly takes front and center stage as a critical source of stem cells for transplants, it has driven the need for consistent quality standards to ensure the safety and efficacy of this life-saving therapy. The newly published results of the landmark COBLT (Cord Blood ...
Pall Prion Removal Technology Presented to FDA Blood Products Advisory Committee
22-03-2005
Pall Corporation presented an overview of the latest research on its prion reduction technology as a new risk reduction measure to help prevent transfusion transmission of infectious prions that can cause vCJD. The Company expects to launch the new filter commercially in Europe this ...
Removing Prions from Blood using Pall Technology
11-02-2005
Assessing the risk of potential exposure to variant Creutzfeldt-Jakob Disease (vCJD) from blood transfusion was the focus of the Food & Drug Administration (FDA) Transmissible Spongiform Encephalopathies (TSEs) Advisory Committee in Silver Spring, Maryland. In response to the Committee's ...
Pall Opens Proteomics Service Centers to Optimize Research and Manufacturing Efficiency
31-01-2005
Pall Corporation launches a comprehensive line of chromatography sorbents. These advanced industry-proven sorbents from Pall greatly simplify protein separation and purification for biotechnology drug discovery, development and production. The integration of this broad range of chromatography ...
Pall Expands Line of Proteomics Technologies for Full Range of Drug Discovery and Development Solutions
Opens Proteomics Service Centers to Optimize Research and Manufacturing Efficiency
11-01-2005
Pall Corporation launches a comprehensive line of chromatography sorbents at PepTalk 2005. These advanced industry-proven sorbents from Pall greatly simplify protein separation and purification for biotechnology drug discovery, development and production. The integration of this broad range ...
Pall Acquires Chromatography Business from Ciphergen
01-12-2004
Pall Corporation announced that it has completed the acquisition of the BioSepra Process Division from Ciphergen Biosystems, Inc. The purchase price was $32 million, net of cash and debt. The BioSepra Process Division develops, manufactures and markets chromatography sorbents that greatly ...
Pall to Acquire Chromatography Business from Ciphergen Biosystems
03-11-2004
Pall Corporation announced it will acquire the BioSepra Process Division from Ciphergen Biosystems, Inc. (Nasdaq: CIPH - News) for a purchase price of approximately $32 million, net of cash and debt. The transaction is expected to close within 45 days. The BioSepra Process Division ...
Netmeeting
